IgG light chain variable region [Homo sapiens]/IgM/kappa antibody [Mus musculus]
(Synonyms: H2N-Thr-Asp-Phe-Thr-Leu-Thr-Ile-OH ) 目录号 : GP10044IgG light chain region
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IgG has four forms, provides the majority of antibody-based immunity against invading pathogens.[1] The only antibody capable of crossing the placenta to give passive immunity to the fetus. IgM is expressed on the surface of B cells (monomer) and in a secreted form (pentamer) with very high avidity. Eliminates pathogens in the early stages of B cell mediated (humoral) immunity before there is sufficient IgG.[2] The immunoglobulin light chain is the small polypeptide subunit of an antibody ( immunoglobulin). Kappa (NJ) chain, one of the two types of light chain in mammals, is encoded by the immunoglobulin kappa locus (IGK@) on chromosome 2. Only V and J segments are found in Ig light chains.[3]
The approximate length of a light chain protein is from 211 to 217 amino acids.[4]
If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma.[5]
Increased levels of free Ig light chains have also been detected in various inflammatory diseases. Very recent studies have shown that Ig light chains not only activate mast cells but also dorsal root ganglia (Rijnierse, 2009)) and neutrophils (Braber and Thio (2012)), expanding their possible role as mediators in inflammatory disease.
References:
1. Pier GB, Lyczak JB, Wetzler LM (2004). Immunology, Infection, and Immunity. ASM Press. ISBN 1-55581-246-5.
2. Geisberger R, Lamers M, Achatz G (2006). "The riddle of the dual expression of IgM and IgD". Immunology 118 (4): 060526021554006 -- . doi: 10.1111 / j. 1365-2567 . 2006.02386.x. PMC 1782314. PMID 16895553
3. Nemazee D (2006). "Receptor editing in lymphocyte development and central tolerance". Nat Rev Immunol 6 (10): 728-740. doi:10.1038/nri1939.PMID 16998507
4. Janeway CA, Jr. et al. (2001). Immunobiology. (5th ed.). Garland Publishing. (electronic full text via NCBI Bookshelf) ISBN 0-8153-3642-X.
5. Leong, Anthony S-Y; Cooper, Kumarason; Leong, F Joel W-M (2003). Manual of Diagnostic Cytology (2 ed.). Greenwich Medical Media, Ltd.. pp. 283-285.ISBN 1-84110-100-1.
Cas No. | SDF | ||
别名 | H2N-Thr-Asp-Phe-Thr-Leu-Thr-Ile-OH | ||
Canonical SMILES | C[C@@H](O)[C@H](N)C(NC(CC(O)=O)C(NC(CC1=CC=CC=C1)C(N[C@@H]([C@@H](O)C)C(NC(CC(C)C)C(N[C@H](C(N[C@H]([C@@H](C)CC)C(O)=O)=O)[C@@H](O)C)=O)=O)=O)=O)=O | ||
分子式 | C37H59N7O13 | 分子量 | 809.9 |
溶解度 | ≥ 81mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.2347 mL | 6.1736 mL | 12.3472 mL |
5 mM | 0.2469 mL | 1.2347 mL | 2.4694 mL |
10 mM | 0.1235 mL | 0.6174 mL | 1.2347 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。